LACTOLOGY FOUNDATION

Racecadotril (ATC A07XA04): Toxicology and Lactation Monograph

Racecadotril is an orally administered intestinal antisecretory antidiarrhoeal prodrug. Its pharmacologically active metabolite, thiorphan, inhibits neutral endopeptidase and thereby potentiates endogenous enkephalins in the gastrointestinal tract. Evidence directly measuring its transfer into human milk or exposure in breastfed infants is lacking; use during lactation therefore requires an individualized benefit–risk assessment.atcddd.fhi+2

ATC class and general pharmacology

ATC code: A07XA04
INN: Racecadotril
ATC group: A07XA — Other antidiarrhoeals

Racecadotril, also known as acetorphan, is an antidiarrhoeal medicine with an antisecretory rather than antimotility mechanism. It is classified as an enkephalinase inhibitor: after oral absorption, racecadotril is rapidly hydrolysed to thiorphan, the principal active metabolite. Thiorphan inhibits neutral endopeptidase (NEP; neprilysin; EC 3.4.24.11), the enzyme responsible for degradation of endogenous enkephalins.genome+1

In the intestinal mucosa, enhanced enkephalin activity reduces intracellular cyclic adenosine monophosphate (cAMP)-dependent secretion of water and electrolytes into the intestinal lumen. The clinical consequence is a reduction in pathological hypersecretion associated with acute diarrhoea, without a primary inhibitory effect on intestinal motility or transit. This distinction is pharmacologically relevant: unlike opioid antimotility drugs, racecadotril is not intended to induce bowel stasis.journals.sagepub+1

Following oral administration, racecadotril is rapidly absorbed and converted to thiorphan. Peak plasma concentrations and measurable plasma NEP inhibition occur early, generally within approximately 1–2 hours. Thiorphan is substantially protein bound—reported at approximately 90%, mainly to albumin—and the pharmacodynamic half-life of NEP inhibition has been reported at about 3 hours. Elimination occurs predominantly through renal excretion of metabolites; faecal elimination represents a smaller pathway.journals.sagepub+2

Toxicological profile

The principal therapeutic pharmacology of racecadotril is peripheral and gastrointestinal. Thiorphan does not readily cross the blood–brain barrier under normal circumstances, which limits direct central nervous system opioid-like activity and helps differentiate racecadotril from centrally active opioid antidiarrhoeals.pmc.ncbi.nlm.nih+1

Clinical tolerability is generally favorable in short-course treatment. Reported adverse effects include headache and, less commonly, dermatological reactions such as rash or erythema. Constipation may occur but was reported during clinical development at rates broadly comparable with placebo. Hypersensitivity reactions are clinically important because racecadotril and related products have been associated with cutaneous reactions; treatment should be stopped and medical assessment obtained if urticaria, angioedema, mucosal lesions, extensive rash, or other signs of serious allergy develop.frontiersin+1

Toxicological concern in acute diarrhoea must not be restricted to the medicine itself. Maternal dehydration, electrolyte imbalance, fever, invasive gastrointestinal infection, and systemic illness may pose a greater immediate clinical risk than pharmacological exposure. Racecadotril is adjunctive therapy and does not replace oral rehydration therapy, nutritional support, diagnostic assessment, or treatment of the underlying cause when indicated.mims

Particular caution is appropriate in severe hepatic or renal impairment because formal data may be limited and systemic handling of active and inactive metabolites could be altered. Evidence concerning use in pregnancy, lactation, and some special populations remains insufficient, warranting conservative clinical decision-making.pmc.ncbi.nlm.nih

Lactation pharmacology and infant exposure

No published human pharmacokinetic studies were identified that quantify racecadotril, thiorphan, or their metabolites in breast milk. Likewise, there are no established milk-to-plasma ratios, relative infant dose calculations, breastfed infant serum concentrations, or controlled outcome studies in nursing infants. This absence of evidence is the central limitation of lactation risk assessment for A07XA04.e-lactation

Several pharmacokinetic features nevertheless suggest that extensive transfer into milk and substantial oral systemic exposure in a healthy term infant may be unlikely:

• Racecadotril is administered orally and is rapidly transformed into thiorphan rather than persisting as substantial parent-drug exposure.
• The active metabolite is approximately 90% protein bound, which usually limits passive diffusion of the unbound fraction into human milk.
• The relevant pharmacological action is principally peripheral and intestinal.
• Maternal treatment is generally short term, reducing the duration of any hypothetical exposure.journals.sagepub+2

These considerations are mechanistic inferences rather than direct evidence of compatibility. Protein binding alone does not establish absence from milk, and the lack of measured infant exposure means that a precise relative infant dose cannot be calculated. Moreover, an infant exposed through milk could theoretically experience gastrointestinal effects, including reduced intestinal fluid secretion, changes in stool frequency or consistency, feeding disturbance, constipation, vomiting, or—less likely—hypersensitivity manifestations.

The clinical relevance of theoretical exposure depends substantially on infant vulnerability. Premature neonates, infants younger than approximately 2 months, infants with renal dysfunction, dehydration, pre-existing gastrointestinal disease, poor feeding, impaired weight gain, or concurrent exposure to other medications warrant a more conservative approach.

Lactological safety assessment and clinical recommendations

Overall lactological assessment: Use with caution; likely low exposure but insufficient direct evidence.

Racecadotril should not automatically require interruption of breastfeeding when a lactating adult has a clear clinical indication for short-term treatment, particularly when effective rehydration and treatment of the underlying diarrhoeal illness are also provided. However, because direct milk-transfer and infant-outcome evidence is absent, it should not be characterized as evidence-proven compatible with breastfeeding. Regulatory and product-information sources may recommend avoiding administration during breastfeeding specifically because excretion in human milk has not been established.e-lactation+1

A pragmatic clinical approach is as follows:

• Prioritize oral rehydration, dietary support, hygiene measures, and assessment for red flags before considering pharmacotherapy.
• Use racecadotril only for an appropriate maternal indication, at the lowest effective dose and for the shortest necessary duration.
• Prefer short-course use in mothers of healthy, full-term infants when the anticipated clinical benefit is meaningful.
• Consider non-pharmacological management or an alternative with more robust lactation data when the nursing infant is preterm, medically unstable, very young, dehydrated, or has relevant gastrointestinal or renal disease.
• Continue breastfeeding when clinically appropriate, while monitoring the infant for altered stool pattern, constipation, poor feeding, vomiting, unusual sleepiness, rash, facial swelling, or inadequate weight gain.
• Obtain prompt medical evaluation for maternal fever, bloody diarrhoea, persistent vomiting, severe abdominal pain, signs of dehydration, suspected infection, or diarrhoea that does not resolve promptly.

Temporary interruption of breastfeeding may be considered in exceptional high-risk situations, but routine “pump and discard” is not supported by direct evidence and may itself compromise lactation. Decisions should be individualized according to maternal disease severity, duration and dose of therapy, infant age and clinical status, availability of alternatives, and the major benefits of continued human milk feeding.

Suggested ToxiLact-style classification: Tier 2 — Limited lactation data / probably low risk with clinical monitoring. This classification reflects favorable pharmacological characteristics and expected short treatment duration, counterbalanced by the absence of published human milk concentrations and infant outcome data.journals.sagepub+2